Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

The future may be getting brighter in terms of reducing the threat of the human immunodeficiency virus (HIV), infectious disease experts told Newsweek. With new treatments and maybe even a vaccine ...

This year we saw more examples of the destructive effort to undermine abortion as a health service. But overreach into health practices was not limited to abortion care.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...